ASCO: It's all tied up? Mirati's KRAS data are 'identical' to...

[cafead]

via The numbers as they stand now don’t lie: Amgen’s Lumakras lasted longer than Mirati’s adagrasib in KRAS-mutated lung cancer. But Mirati's CEO still has high hopes for adagrasib, as an investigator of a study into the latecomer drug told Fierce Biotech that the two therapies have shown "essentially identical" efficacy.

article source